Wall Street brokerages expect that MacroGenics, Inc. (NASDAQ:MGNX) will post earnings per share of ($1.03) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for MacroGenics’ earnings. The highest EPS estimate is ($0.77) and the lowest is ($1.21). MacroGenics reported earnings per share of ($0.97) in the same quarter last year, which suggests a negative year over year growth rate of 6.2%. The business is expected to issue its next quarterly earnings results on Wednesday, November 1st.

On average, analysts expect that MacroGenics will report full-year earnings of ($4.27) per share for the current year, with EPS estimates ranging from ($4.69) to ($3.77). For the next year, analysts forecast that the company will report earnings of ($3.96) per share, with EPS estimates ranging from ($4.76) to ($3.18). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for MacroGenics.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.09). MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $15.82 million. During the same quarter in the previous year, the company posted $1.12 EPS. The company’s revenue for the quarter was down 97.9% compared to the same quarter last year.

Several analysts have issued reports on MGNX shares. Wedbush reaffirmed an “outperform” rating and issued a $44.00 price objective on shares of MacroGenics in a research report on Monday, September 11th. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a research report on Friday, August 4th. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating and set a $19.00 price objective for the company in a research report on Tuesday, July 18th. BidaskClub downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, Morgan Stanley lowered their price objective on shares of MacroGenics from $22.00 to $21.00 and set an “equal weight” rating for the company in a research report on Monday, August 7th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.30.

Shares of MacroGenics (NASDAQ:MGNX) traded up 2.05% on Friday, reaching $17.45. 317,331 shares of the company’s stock were exchanged. The firm’s market capitalization is $642.13 million. MacroGenics has a one year low of $14.36 and a one year high of $32.68. The firm has a 50 day moving average of $17.02 and a 200 day moving average of $18.38.

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in shares of MacroGenics during the second quarter worth approximately $133,000. Legal & General Group Plc grew its position in shares of MacroGenics by 4.3% during the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 328 shares in the last quarter. SG Americas Securities LLC grew its position in shares of MacroGenics by 92.2% during the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 5,187 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of MacroGenics during the second quarter worth approximately $203,000. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of MacroGenics during the second quarter worth approximately $232,000. 84.47% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/16/macrogenics-inc-mgnx-expected-to-announce-earnings-of-1-03-per-share.html.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.